Nutriband (NASDAQ:NTRB) Share Price Breaks Above 50 Day Moving Average – Should You Sell?

Shares of Nutriband Inc. (NASDAQ:NTRB) passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $6.25 and traded as high as $6.41. Nutriband shares last traded at $6.4750, with a volume of 71,074 shares changing hands.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NTRB. Weiss Ratings reissued a “sell (d-)” rating on shares of Nutriband in a research report on Monday, September 28th. Wall Street Zen upgraded shares of Nutriband to a “hold” rating in a research note on Saturday, October 17th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nutriband has a consensus rating of “Reduce”.

Nutriband Trading Down 5.1%

The firm has a market capitalization of $76.58 million, a price-to-earnings ratio of -11.89 and a beta of 1.92. The stock’s fifty day moving average price is $6.36 and its two-hundred day moving average price is $4.37.

Nutriband (NASDAQ:NTRB) last issued its earnings results on Friday, September 4th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.44 million for the quarter. Nutriband had a negative return on equity of 109.07% and a negative net margin of 430.35%.

Nutriband Company Profile

Nutriband Inc is a medical technology company focused on developing and commercializing transdermal and topical products. The company’s platform is designed to deliver active pharmaceutical ingredients through the skin, with applications in prescription medicines, over-the-counter products, consumer health, and veterinary care.

Nutriband also provides contract manufacturing and product development services for transdermal patches and related products. Its offerings include adhesive patches and other topical delivery formats, as well as formulation, manufacturing, packaging, and regulatory support for customers developing transdermal therapies.

The company’s proprietary AVERSA technology is intended to incorporate abuse-deterrent and tamper-resistant features into transdermal drug-delivery systems.